Machine learning multiomics Deciphers GRHL2 associated tumor microenvironment evolution guiding precision therapeutics in breast cancer

Grainyhead-like 2 (GRHL2) has been implicated in various cancers, but its role in breast cancer (BRCA) remains poorly understood. This study aims to comprehensively characterize the prognostic and immunological significance of GRHL2 in BRCA using multi-omics data. We analyzed single-cell RNA sequencing (scRNA-seq) data and multiple bulk RNA-seq datasets. Tumor cells were identified using InferCNV, and prognostic genes were refined via CoxBoost regression. GRHL2 was identified as a risk factor associated with poor survival in multiple cohorts. Functional enrichment analysis revealed its involvement in key oncogenic pathways. Furthermore, GRHL2 expression correlated with immune infiltration patterns, immunomodulator expression, and somatic mutation profiles. Drug sensitivity analysis suggested potential therapeutic agents targeting GRHL2-related pathways. Collectively, our findings highlight GRHL2 as a promising prognostic biomarker for risk stratification and a candidate therapeutic target, with specific implications for guiding immunotherapy and targeted treatment strategies in BRCA.

Authors

Institutions

Publication Details

Journal
Discover Oncology
Published
2025-11-23
DOI
https://doi.org/10.1007/s12672-025-04120-8
Primary Topic
Ferroptosis and cancer prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Machine learning multiomics Deciphers GRHL2 associated tumor microenvironment evolution guiding precision therapeutics in breast cancer

Zhengkuo Wei, Yuanyuan Zhu, Jingjing Zhao, Jun Tang
Discover Oncology
Ferroptosis and cancer prognosis
article

Machine learning multiomics Deciphers GRHL2 associated tumor microenvironment evolution guiding precision therapeutics in breast cancer

Zhengkuo Wei, Yuanyuan Zhu, Jingjing Zhao, Jun Tang
article en

Abstract

Grainyhead-like 2 (GRHL2) has been implicated in various cancers, but its role in breast cancer (BRCA) remains poorly understood. This study aims to comprehensively characterize the prognostic and immunological significance of GRHL2 in BRCA using multi-omics data. We analyzed single-cell RNA sequencing (scRNA-seq) data and multiple bulk RNA-seq datasets. Tumor cells were identified using InferCNV, and prognostic genes were refined via CoxBoost regression. GRHL2 was identified as a risk factor associated with poor survival in multiple cohorts. Functional enrichment analysis revealed its involvement in key oncogenic pathways. Furthermore, GRHL2 expression correlated with immune infiltration patterns, immunomodulator expression, and somatic mutation profiles. Drug sensitivity analysis suggested potential therapeutic agents targeting GRHL2-related pathways. Collectively, our findings highlight GRHL2 as a promising prognostic biomarker for risk stratification and a candidate therapeutic target, with specific implications for guiding immunotherapy and targeted treatment strategies in BRCA.

Discover OncologyVol. 16(1)
Hubei University of Medicine (CN), Hubei University of Arts and Science (CN), Xiang Yang No.1 People's Hospital (CN)
Openalex Percentile: Top 49%
Ferroptosis and cancer prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.